Early Signal Diagnostics Launches 10,000-Patient Study in Bogotá
News related to:Early Signal Diagnostics Corp · 1 min read
BEVERLY HILLS, CA, UNITED STATES, October 19, 2026 /CourierPR/ -- Early Signal Diagnostics Corp is set to launch a significant validation study in early 2027, involving 10,000 patients in Bogotá, Colombia. The study will focus on evaluating the company’s AI-driven biomarker platform for its ability to detect pancreatic and ovarian cancers from a capillary blood sample.
The validation study, which will take place at two laboratories in Bogotá, Colombia, marks a crucial step in the company’s mission to develop and rigorously test its AI-driven diagnostic tools. Early Signal Diagnostics believes that AI biomarkers should be validated with the same rigor as companion diagnostics, and conducting the study in a Latin American population will help test the platform’s performance across diverse patient groups.
According to Todd Wright, the VP of International Operations at Early Signal Diagnostics Corp, the company has seen a strong commitment to earlier cancer detection in Bogotá.
The company’s platform applies single-cell RNA sequencing analysis and machine learning to cancer biomarker discovery. Recent work has identified a novel set of oncogenes and tumor suppressor genes not previously recognized in pancreatic and ovarian cancer, findings that may point to actionable targets for therapeutic intervention.
Early Signal Diagnostics Corp, headquartered in Cathedral City, California, develops diagnostic tests for early disease detection. The company combines single-cell RNA sequencing analysis and machine learning to identify biomarkers that may help clinicians find disease sooner. The study will enroll approximately 10,000 local patients and will evaluate the platform’s ability to detect ovarian and pancreatic cancer from a capillary blood sample.
Early Signal Diagnostics believes AI biomarkers should be validated with the same rigor as companion diagnostics. Conducting the study in a Latin American population also tests whether the platform performs across diverse patient groups, a common gap in AI biomarker research.
The participating laboratories will be announced once agreements are finalized. Preliminary results are expected approximately nine months after the validation studies begin.